

ACEP Statement on Antitussives

llene Claudius, MD and Anand Swaminathan, MD

- Antitussive agents (both by prescription and over the counter) are frequently used in the pediatric population
- ACEP Policy statement in 2020 argues against their use
- Codeine containing medications
 - ACEP supports FDA statement
 - O Do not use in pediatric patients < 12 or in those 12-18 who are obese, have sleep apnea or underlying lung disease due to risk of apnea and death
- Dextromethorphan containing medications
 - Risk of side effects is high
 - Abuse potential particularly in older children
- Benzonatate containing medications
 - Benzonatate is active ingredient in tessalon pearls
 - Recommend against due to lack of efficacy and potential side effects
 - Side effects: restlessness, tremor, seizures, cardiac arrest
- Studies have not shown benefit for dextromethorphan, promethazine, echinacea or inhaled corticosteroids over placebo
- Honey
 - Shown to be superior to placebo in children > 1 year of age
 - Avoid in children < 1 year of age for concern for botulism

Links:

- https://www.acep.org/patient-care/policy-statements/use-of-antitussive-medica-tions-in-the-pediatric-population/
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007094.pub5/full

Cardiology Corner: Kounis Syndrome

Amal Mattu, MD and Susy Demeester, MD

- Kounis Syndrome is an acute coronary syndrome caused by an allergic reaction.
- It is named for Nicholas Kounis, who in 1991 coined the term "allergic angina."
- The syndrome is associated with MAST cell activation, histamine reaction, and platelet aggregation. This inflammation results in coronary plaque rupture, with or without vasospasm.